Takeda pays $13.6 million over Trintellix speaker program kickback allegations

By ··2 min read

Takeda Pharmaceuticals U.S.A. Inc. has agreed to pay $13,670,921 to resolve Department of Justice allegations that it paid kickbacks to healthcare providers, in the form of speaker honoraria and high-end meals, to induce prescriptions of the antidepressant Trintellix. The government alleged the conduct caused false claims to Medicare and other federal programmes.

Takeda Pharmaceuticals U.S.A. Inc. has agreed to pay $13,670,921 to resolve allegations that it knowingly caused the submission of false claims to Medicare and other federal healthcare programmes by paying kickbacks to healthcare providers to induce prescriptions of Trintellix, an antidepressant marketed for major depressive disorder. The Department of Justice announced the settlement on May 14, 2026.

The civil settlement resolves allegations that from January 2014 to October 2020 Takeda provided improper remuneration, including speaker honoraria and meals at high-end restaurants, to induce prescribing in violation of the Anti-Kickback Statute. The statute prohibits offering or paying anything of value to induce referrals of items or services covered by Medicare, Medicaid, TRICARE and other federal programmes. The government contends that Takeda selected certain providers for its Trintellix speaker bureau with the intent that honoraria and meals would induce them to prescribe the drug, and that some prescribers attended multiple programmes on the same topic without any educational benefit.

The Justice Department's announcement did not include a statement from Takeda. The department noted that the claims resolved are allegations only and that there has been no determination of liability.

The case adds to sustained federal scrutiny of pharmaceutical speaker programmes, which HHS-OIG flagged as a high-risk practice in a 2020 Special Fraud Alert. Officials from the Civil Division, the US Attorney's Office for the Eastern District of California, HHS-OIG and the Defense Criminal Investigative Service each emphasised the risk that such payments distort prescribing decisions. The theory of liability — that repeat attendance at speaker events with no educational value evidences improper inducement — mirrors allegations the department has advanced in other manufacturer cases.

The matter was handled by the Civil Division's Commercial Litigation Branch, Fraud Section, and the US Attorney's Office for the Eastern District of California, with assistance from DCIS and HHS-OIG. The announcement did not reference a whistleblower complaint or a corporate integrity agreement, and no further proceedings were announced.

Cite this report

The Precedent. "Takeda pays $13.6 million over Trintellix speaker program kickback allegations." September 3, 2026. https://theprecedent.org/article/takeda-pays-136-million-over-trintellix-speaker-program-kickback-allegations